Is BIIB a good stock to buy right now?

Based on our 6-factor quantitative model, BIOGEN INC. (BIIB) receives a "Hold" rating with a composite score of 49.9/100. It is ranked #1,061 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 59/100, Momentum 57/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for BIIB?

BIOGEN INC. (BIIB) has a "Hold" rating and 3-star score. The composite score of 49.9 ranks it #1,061 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is BIIB in?

BIOGEN INC. operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $26.97 billion. It is classified as a large-cap stock.

Does BIIB pay a dividend?

BIIB does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is BIIB's P/E ratio?

BIIB has a trailing P/E ratio of 14.89x. The Healthcare sector average is 23.6x. This below-average P/E may indicate the stock is undervalued.

How profitable is BIIB?

BIIB's quality factor score is 50/100. Gross margin: 74.7%. ROE: 9.5% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is BIIB valued compared to peers?

BIIB's value factor score is 59/100 (higher = cheaper). Key multiples: P/E 14.9x, EV/EBITDA 15.5x. Valuation is roughly in line with peers.

What is BIIB's debt level?

BIIB's debt-to-equity ratio is 34%. Sector average: 32%. Low leverage suggests conservative financial management.

BIIB has a beta of 0.67, meaning it is less volatile than the market. Stability score: 75/100.

Does BIIB have high short interest?

BIIB's short interest factor score is 11/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

BIIB Stock Analysis: Hold (Score 49.9/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
BIIB	-2.34%	-2.46%	-8.19%	-1.72%	+52.56%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-2.27%	-6.07%	-8.53%	-1.36%	+23.03%	-	-	-
Alpha vs Sector	-0.98%	-2.80%	-4.38%	+3.12%	+43.35%	-	-	-

Metric	BIIB	Benchmark
P/E Ratio	14.9x	-37%
EV/EBITDA	15.5x	+145%
Price / Book	1.4x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
BIIB BIOGEN INC.	50	50	59	57	14.9x	9.5%	74.7%	17.0%	2.8%	34.0x	$27.0B
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.7%	0.8%	0.8%	0.7%	0.8%	0.8%	0.9%	0.9%	0.9%	0.9%	0.9%
Operating Margin %	0.2%	0.2%	0.2%	0.1%	0.4%	0.3%	0.3%	0.5%	0.4%	0.4%	0.5%
EBITDA Margin %	0.2%	0.2%	0.3%	0.1%	0.4%	0.3%	0.4%	0.5%	0.5%	0.5%	0.5%
Net Margin %	0.2%	0.1%	0.2%	0.1%	0.3%	0.2%	0.3%	0.4%	0.3%	0.2%	0.3%
FCF Margin %	-	-	28.1%	-	-	-	28.3%	43.6%	29.1%	20.2%	24.2%
ROE %	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.4%	0.4%	0.3%	0.2%	0.3%
ROA %	0.1%	0.0%	0.1%	0.0%	0.1%	0.1%	0.2%	0.2%	0.2%	0.1%	0.2%
ROIC %	0.1%	5.0%	7.3%	4.7%	14.4%	13.0%	21.4%	34.0%	26.2%	24.9%	24.9%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.7%

0.8%

0.7%

0.8%

0.9%

Operating Margin %

0.2%

0.1%

0.4%

0.3%

0.5%

0.4%

0.5%

EBITDA Margin %

0.2%

0.3%

0.1%

0.4%

0.3%

0.4%

0.5%

Net Margin %

0.2%

0.1%

0.2%

0.1%

0.3%

0.2%

0.3%

0.4%

0.3%

0.2%

0.3%

FCF Margin %

28.1%

28.3%

43.6%

29.1%

20.2%

24.2%

ROE %

0.1%

0.2%

0.4%

0.3%

0.2%

0.3%

ROA %

0.1%

0.0%

0.1%

0.0%

0.1%

0.2%

0.1%

0.2%

ROIC %

0.1%

5.0%

7.3%

4.7%

14.4%

13.0%

21.4%

34.0%

26.2%

24.9%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$10.1B	$9.9B	$9.7B	$9.8B	$10.2B	$11.0B	$13.4B	$14.4B	$13.5B	$12.3B	$11.4B	$10.8B
	—	$2.4B	—	$2.5B	$2.3B	$2.1B	—	—	—	—	—	—
	$7.5B	$7.5B	$7.4B	$7.3B	$7.9B	$8.9B	$11.6B	$12.4B	$11.6B	$10.6B	$10.0B	$9.5B
Gross Margin	74.7%	75.7%	76.1%	74.2%	77.6%	80.8%	86.6%	86.4%	86.5%	86.7%	87.1%	88.5%
	—	$2.4B	—	$2.5B	$2.4B	$2.7B	—	—	—	—	—	—
Research & Development	—	—	$2.0B	—	—	—	$4.1B	$2.3B	$2.7B	$2.4B	$2.0B	$2.0B
Depreciation	—	—	$903M	—	—	—	$457M	$681M	$1.0B	$1.1B	$683M	$600M
Total Operating Expenses	—	$5.9B	—	$6.0B	$4.3B	$6.0B	—	—	—	—	—	—
	$2.1B	$1.6B	$1.9B	$1.3B	$3.6B	$2.8B	$4.6B	$7.0B	$5.9B	$5.3B	$5.2B	$4.9B
EBIT	$2.1B	$1.6B	$1.9B	$1.3B	$3.6B	$2.8B	$4.6B	$7.0B	$5.9B	$5.3B	$5.2B	$4.9B
EBITDA	$2.1B	$1.6B	$2.8B	$1.3B	$3.6B	$2.8B	$5.5B	$7.6B	$6.6B	$6.2B	$5.6B	$5.4B
Operating Margin	20.3%	15.7%	23.3%	13.2%	35.3%	25.9%	33.8%	49.0%	43.8%	43.5%	45.0%	45.4%
EBITDA Margin	20.5%	15.7%	29.0%	13.2%	35.3%	25.9%	40.9%	52.8%	48.7%	50.6%	49.1%	49.9%
	—	$268M	—	$247M	$247M	$254M	—	—	—	—	—	—
	—	$1.6B	—	$1.3B	$3.6B	$1.7B	—	—	—	—	—	—
Income Tax Expense	—	$264M	$274M	$135M	$633M	$53M	$992M	$1.2B	$1.4B	$2.5B	$1.2B	$1.2B
	$1.7B	$1.3B	$1.6B	$1.2B	$3.0B	$1.7B	$4.1B	$5.9B	$4.5B	$2.7B	$3.7B	$3.6B
Net Margin	17.0%	13.1%	16.9%	11.8%	29.1%	15.7%	30.2%	41.0%	33.3%	21.8%	32.3%	33.4%
	$8.83	$8.83	$11.21	$8.02	$20.96	$10.44	$24.86	$31.47	$21.63	$11.94	$16.96	$15.38
Diluted EPS	$8.83	$8.79	$11.21	$7.97	$20.87	$10.40	$24.86	$31.47	$21.63	$11.94	$16.96	$15.38
Weighted Avg Basic	—	147M	—	145M	145M	149M	—	—	—	—	—	—
Weighted Avg Diluted	—	147M	—	146M	146M	150M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$10.1B

$9.9B

$9.7B

$9.8B

$10.2B

$11.0B

$13.4B

$14.4B

$13.5B

$12.3B

$11.4B

$10.8B

—

$2.4B

—

$2.5B

$2.3B

$2.1B

—

$7.5B

$7.4B

$7.3B

$7.9B

$8.9B

$11.6B

$12.4B

$11.6B

$10.6B

$10.0B

$9.5B

Gross Margin

74.7%

75.7%

76.1%

74.2%

77.6%

80.8%

86.6%

86.4%

86.5%

86.7%

87.1%

88.5%

—

$2.4B

—

$2.5B

$2.4B

$2.7B

—

Research & Development

—

$2.0B

—

$4.1B

$2.3B

$2.7B

$2.4B

$2.0B

Depreciation

—

$903M

—

$457M

$681M

$1.0B

$1.1B

$683M

$600M

Total Operating Expenses

—

$5.9B

—

$6.0B

$4.3B

$6.0B

—

$2.1B

$1.6B

$1.9B

$1.3B

$3.6B

$2.8B

$4.6B

$7.0B

$5.9B

$5.3B

$5.2B

$4.9B

EBIT

$2.1B

$1.6B

$1.9B

$1.3B

$3.6B

$2.8B

$4.6B

$7.0B

$5.9B

$5.3B

$5.2B

$4.9B

EBITDA

$2.1B

$1.6B

$2.8B

$1.3B

$3.6B

$2.8B

$5.5B

$7.6B

$6.6B

$6.2B

$5.6B

$5.4B

Operating Margin

20.3%

15.7%

23.3%

13.2%

35.3%

25.9%

33.8%

49.0%

43.8%

43.5%

45.0%

45.4%

EBITDA Margin

20.5%

15.7%

29.0%

13.2%

35.3%

25.9%

40.9%

52.8%

48.7%

50.6%

49.1%

49.9%

—

$268M

—

$247M

$254M

—

$1.6B

—

$1.3B

$3.6B

$1.7B

—

Income Tax Expense

—

$264M

$274M

$135M

$633M

$53M

$992M

$1.2B

$1.4B

$2.5B

$1.2B

$1.7B

$1.3B

$1.6B

$1.2B

$3.0B

$1.7B

$4.1B

$5.9B

$4.5B

$2.7B

$3.7B

$3.6B

Net Margin

17.0%

13.1%

16.9%

11.8%

29.1%

15.7%

30.2%

41.0%

33.3%

21.8%

32.3%

33.4%

$8.83

$11.21

$8.02

$20.96

$10.44

$24.86

$31.47

$21.63

$11.94

$16.96

$15.38

Diluted EPS

$8.83

$8.79

$11.21

$7.97

$20.87

$10.40

$24.86

$31.47

$21.63

$11.94

$16.96

$15.38

Weighted Avg Basic

—

147M

—

145M

149M

—

Weighted Avg Diluted

—

147M

—

146M

150M

—

BIOGEN INC. (BIIB) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does BIOGEN INC. Do?

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. BIOGEN INC. (BIIB) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Christopher A. Viehbacher and employs approximately 8,720 people, headquartered in Weston, Massachusetts. With a market capitalization of $27.0B, BIIB is one of the prominent companies in the Healthcare sector.

BIOGEN INC. (BIIB) Stock Rating — Hold (April 2026)

As of April 2026, BIOGEN INC. receives a Hold rating with a composite score of 49.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.BIIB ranks #1,061 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BIOGEN INC. ranks #75 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BIIB Stock Price and 52-Week Range

BIOGEN INC. (BIIB) currently trades at $172.97. The stock lost $4.14 (2.3%) in the most recent trading session. The 52-week high for BIIB is $202.41, which means the stock is currently trading -14.5% from its annual peak. The 52-week low is $110.03, putting the stock 57.2% above its annual trough. Recent trading volume was 1.5M shares, reflecting moderate market activity.

Is BIIB Overvalued or Undervalued? — Valuation Analysis

BIOGEN INC. (BIIB) carries a value factor score of 59/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 14.89x, compared to the Healthcare sector average of 23.63x — a discount of 37%. The price-to-book ratio stands at 1.41x, versus the sector average of 2.75x. The price-to-sales ratio is 2.56x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, BIIB trades at 15.54x EV/EBITDA, versus 6.34x for the sector.

Overall, BIIB's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

BIOGEN INC. Profitability — ROE, Margins, and Quality Score

BIOGEN INC. (BIIB) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 9.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 5.9% versus the sector average of -33.1%.

On a margin basis, BIOGEN INC. reports gross margins of 74.7%, compared to 71.5% for the sector. The operating margin is 20.3% (sector: -66.1%). Net profit margin stands at 17.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 2.8% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

BIIB Debt, Balance Sheet, and Financial Health

BIOGEN INC. has a debt-to-equity ratio of 34.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.68x, indicating strong short-term liquidity. Total debt on the balance sheet is $6.29B. Cash and equivalents stand at $3.86B.

BIIB has a beta of 0.67, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for BIOGEN INC. is 75/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

BIOGEN INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, BIOGEN INC. reported revenue of $10.08B and earnings per share (EPS) of $8.83. Net income for the quarter was $1.73B. Gross margin was 74.7%. Operating income came in at $2.06B.

In FY 2025, BIOGEN INC. reported revenue of $9.89B and earnings per share (EPS) of $8.83. Net income for the quarter was $1.29B. Gross margin was 75.7%. Revenue grew 2.2% year-over-year compared to FY 2024. Operating income came in at $1.56B.

In Q3 2025, BIOGEN INC. reported revenue of $2.53B and earnings per share (EPS) of $3.18. Net income for the quarter was $467M. Gross margin was 73.4%. Revenue grew 2.8% year-over-year compared to Q3 2024. Operating income came in at $557M.

In Q2 2025, BIOGEN INC. reported revenue of $2.65B and earnings per share (EPS) of $4.33. Net income for the quarter was $635M. Gross margin was 77.1%. Revenue grew 7.3% year-over-year compared to Q2 2024. Operating income came in at $744M.

Over the past 8 quarters, BIOGEN INC. has demonstrated a growth trajectory, with revenue expanding from $2.46B to $10.08B. Investors analyzing BIIB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BIIB Dividend Yield and Income Analysis

BIOGEN INC. (BIIB) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BIIB Momentum and Technical Analysis Profile

BIOGEN INC. (BIIB) has a momentum factor score of 57/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 11/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

BIIB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BIOGEN INC. (BIIB) ranks #75 out of 838 stocks based on the Blank Capital composite score. This places BIIB in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BIIB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BIIB vs S&P 500 (SPY) comparison to assess how BIOGEN INC. stacks up against the broader market across all factor dimensions.

BIIB Next Earnings Date

No upcoming earnings date has been announced for BIOGEN INC. (BIIB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BIIB? — Investment Thesis Summary

BIOGEN INC. presents a balanced picture with arguments on both sides. Low volatility (stability score 75/100) reduces downside risk.

In summary, BIOGEN INC. (BIIB) earns a Hold rating with a composite score of 49.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BIIB stock.

Related Resources for BIIB Investors

Explore more research and tools: BIIB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BIIB head-to-head with peers: BIIB vs AZN, BIIB vs SLGL, BIIB vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Gilead Expands Oncology Pipeline With $5B Tubulis Deal

1 S&P 500 Stock for Long-Term Investors and 2 We Ignore

Cures: A father and a doctor on how raising a child with Angelman syndrome changed him

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

BIOGEN INC. (BIIB) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does BIOGEN INC. Do?

BIOGEN INC. (BIIB) Stock Rating — Hold (April 2026)

BIIB Stock Price and 52-Week Range

Is BIIB Overvalued or Undervalued? — Valuation Analysis

BIOGEN INC. Profitability — ROE, Margins, and Quality Score

BIIB Debt, Balance Sheet, and Financial Health

BIOGEN INC. Revenue and Earnings History — Quarterly Trend

BIIB Dividend Yield and Income Analysis

BIIB Momentum and Technical Analysis Profile

BIIB vs Competitors — Healthcare Sector Ranking and Peer Comparison

BIIB Next Earnings Date

Should You Buy BIIB? — Investment Thesis Summary

Related Resources for BIIB Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Gilead Expands Oncology Pipeline With $5B Tubulis Deal

1 S&P 500 Stock for Long-Term Investors and 2 We Ignore

Cures: A father and a doctor on how raising a child with Angelman syndrome changed him